Buscador de Personas - SIGEVA - Universidad Nacional de Córdoba

Traumatic brain injury (TBI) is a global public health concern. It is the leading cause of death in the population under forty years old and after that, it remains as one of the main. TBI-related injuries are divided in 2 subcategories: primary injury, which occurs at the moment of trauma, and secondary injury, which occurs immediately after trauma and produces effects that may continue for a long period of time. The latter is attributable to further cellular damage from the effects of primary injuries and related to inflammatory mechanisms and oxidative stress (OS) and could by themselves have severe consequences. Secondary injuries may develop over a period of hours or days following the initial traumatic assault and this delayed nature suggests that there is a window for therapeutic intervention to prevent progressive tissue damage and improve functional recovery after injury. Among survivors, neurological impairment may vary from subtle symptoms to severe long term sequelae, either physical as long as cognitive. To date, there is no treatment to target mechanisms of secondary injury and the therapeutic arsenal is limited to decrease intracranial pressure. Non-steroidal anti-inflammatory drugs and steroids are not effective in the treatment of TBI because of their limited access to central nervous system. A therapeutic alternative of increasing interest in the treatment of brain injuries, is the use of neurotropic factors such as Insulin-like growth factor 1 (IGF-1), since they are neuromodulators associated with neuroprotection and anti-inflammatory effects.ObjectiveThe aim of the present investigation is to evaluate the effectiveness of IGF-1 in the treatment of TBI in both reversing OS as well as improving cognitive deficits.

enviar mensaje